Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ADMA Biologics (ADMA)

ADMA Biologics: Director Bryant Fong resigns from board, effective immediately

Neutral Impact 2 of 5 leadership Written later

ADMA Biologics disclosed that Bryant E. Fong resigned from its Board of Directors and all committees effective immediately, to devote more time to his outside roles. The filing states there were no disagreements with the company, and Mr. Fong had served on the board since 2012. The company also named committee replacements, which matters to shareholders because it changes who oversees audit and governance.

Key points

  • Bryant E. Fong resigned effective immediately on November 19, 2024, citing more time for outside roles at Biomark Capital Fund and Stonepine Capital Management
  • Mr. Fong had served on the board since 2012 and was Chairman of the Audit Committee
  • Young T. Kwon, PhD was appointed Audit Committee Chairman and designated an audit committee financial expert on November 19, 2024
  • Steven A. Elms joined the Audit Committee; Alison C. Finger joined the Governance and Nominations and Compensation Committees

The filing

CompanyADMA Biologics (ADMA)
Form8-K, current report
Filed with the SECNov 21, 2024, 4:30 PM ET
Accession number0001140361-24-047487

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:49 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 21, 2024.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.